Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA20012856978579511176917
   PubMedGoogle Scholar
• Consensus Development SummariesEstrogen use and postmenopausal women. Sponsored by the National Institute on Aging, assisted by the Office for Medical Applications of Research, NIHConn Med19804428587887363614
   PubMedGoogle Scholar
• IkiMEpidemiology of osteoporosis in JapanClin Calcium2012226797803 Japanese22653016
   PubMedGoogle Scholar
• KwokAWLeungJCChanAYPrevalence of vertebral fracture in Asian men and women: comparison between Hong Kong, Thailand, Indonesia and JapanPublic Health2012126652353122560410
   PubMed Web of Science ®Google Scholar
• PapapoulosSEThe role of bisphosphonates in the prevention and treatment of osteoporosisAm J Med1993955A48S52S8256796
   PubMed Web of Science ®Google Scholar
• TucciJRToninoRPEmkeyRDPeverlyCAKherUSantoraAC2ndEffect of three years of oral alendronate treatment in postmenopausal women with osteoporosisAm J Med199610154885018948272
   PubMed Web of Science ®Google Scholar
• DevogelaerJPBrollHCorrea-RotterROral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone19961821411508833208
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBrollJEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med199533322143714437477143
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEApplegateWBBarrett-ConnorEMuslinerTAPalermoLPrineasRRubinSMScottJCVogtTWallaceRYatesAJLaCroixAZEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA199828024207720829875874
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDAMultinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study GroupOsteoporos Int19999546146810550467
   PubMed Web of Science ®Google Scholar
• EnsrudKEBlackDMPalermoLTreatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention TrialArch Intern Med199715722261726249531231
   PubMed Web of Science ®Google Scholar
• BoneHGHoskingDDevogelaerJPAlendronate Phase III Osteoporosis Treatment Study GroupTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med2004350121189119915028823
   PubMed Web of Science ®Google Scholar
• EnsrudKEBarrett-ConnorELSchwartzAFracture Intervention Trial long-Term Extension Research GroupRandomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionJ Bone Miner Res20041981259126915231012
   PubMed Web of Science ®Google Scholar
• OdvinaCVZerwekhJERaoDSMaaloufNGottschalkFAPakCYSeverely suppressed bone turnover: a potential complication of alendronate therapyJ Clin Endocrinol Metab20059031294130115598694
   PubMed Web of Science ®Google Scholar
• ImaiKYamamotoSAnamizuYHoriuchiTPelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapyJ Bone Miner Metab200725533333617704999
   PubMed Web of Science ®Google Scholar
• ChiuWYLeeJJTsaiKSAtypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosisJ Clin Endocrinol Metab2013984E723E72623471975
   PubMed Web of Science ®Google Scholar
• NaganoYMatsuiHShimokawaOBisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidationJ Clin Biochem Nutr201251319620323170047
   PubMed Web of Science ®Google Scholar
• SugiharaMAwazuSUedaKTakedaYFukumuroK[Studies for the construction of new pharmaceutical preparations and new packaging containers optimal for administration to elderly subjects]1988 Japanese
   Google Scholar
• SugiharaMThe Pharmaceuticals Monthly19963817031706 Japanese
   Google Scholar
• MostafaHFIbrahimMASakrADevelopment and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variablesPharm Dev Technol201318245446322881389
   PubMed Web of Science ®Google Scholar
• DairakuMTogashiMDevelopment of Air Push Jelly Formulation and Packaging DesignHosogijutsu Zasshi (Japan Packaging Institute)20034110836841 Japanese
   Google Scholar
• SakashitaYSakuraiSYakouSIshizukaHYanagawaCClinical usefulness of jelly preparation, new formulation for medical drugPharm Tech Japan2003191323672377 Japanese
   Google Scholar
• DairakuMTogashiMDevelopment of Air Push Jelly FormulationYakuzaigaku (J pharm sci technol Japan)2005654209214 Japanese
   Google Scholar
• HanawaTDevelopment of the new oral dosage forms for elderly patientsNippon Ronen Igakkai Zasshi2008455485488 Japanese19057097
   PubMedGoogle Scholar
• HanawaTTokutakeNOguchiTQuestionnaire survey of air extruded jelly dosage form (I) – oral condition of elder patients and applicability of air extruded jelly formulation –Yakugaku Zasshi20121321214611466 Japanese22986222
   PubMed Web of Science ®Google Scholar
• FukaseHMiyagiFSaitoKItoNBioequivalence of Bonalon® Oral Jelly 35 mg versus Bonalon® Tablet 35 mgShinyaku and Rinsho (Journal of New Remedies and Clinics)201261918331847 Japanese
   Google Scholar
• KarpfDBShapiroDRSeemanEPrevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study GroupsJAMA199727714115911649087473
   PubMed Web of Science ®Google Scholar
• SharpeMNobleSSpencerCMAlendronate: an update of its use in osteoporosisDrugs2001617999103911434454
   PubMed Web of Science ®Google Scholar
• CranneyAWellsGWillanAOsteoporosis Methodology Group and The Osteoporosis Research Advisory GroupMeta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal womenEndocr Rev200223450851612202465
   PubMed Web of Science ®Google Scholar
• GreenspanSLSchneiderDLMcClungMRAlendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trialAnn Intern Med20021361074274612020142
   PubMed Web of Science ®Google Scholar
• PapapoulosSEQuandtSALibermanUAHochbergMCThompsonDEMeta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal womenOsteoporos Int200516546847415448985
   PubMed Web of Science ®Google Scholar
• DavisJWNovotnyRRossPDWasnichRDThe peak bone mass of Hawaiian, Filipino, Japanese, and white women living in HawaiiCalcif Tissue Int19945542492527820774
   PubMed Web of Science ®Google Scholar
• NordinBEInternational patterns of osteoporosisClin Orthop Relates Res1966451730
   PubMedGoogle Scholar
• ShirakiMKushidaKFukunagaMA placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research GroupEndocr J19984521912019700472
   PubMed Web of Science ®Google Scholar
• NakamuraTKushidaKShirakiMDose-range finding study of alendronate in the treatment of the patients with involutional osteoporosis and postmenopausal womenJ New Remedies Clin199735317 Japanese
   Google Scholar
• ShirakiMKushidaKFukunagaMA double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research GroupOsteoporos Int199910318319210525709
   PubMed Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTThe efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trialCurr Ther Res Clin Exp200263606620
   Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab200422546246815316867
   PubMed Web of Science ®Google Scholar
• ImaiKOhnishiIMatsumotoTYamamotoSNakamuraKAssessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element methodOsteoporosis Int2009205801810
   Web of Science ®Google Scholar
• ImaiKVertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element methodJ Bone Miner Metab201129664565121667358
   PubMed Web of Science ®Google Scholar
• SeedorJGQuartuccioHAThompsonDDThe bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in ratsJ Bone Miner Res1991643393461858520
   PubMed Web of Science ®Google Scholar
• BalenaRToolanBCSheaMThe effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primatesJ Clin Invest1993926257725868254015
   PubMed Web of Science ®Google Scholar
• PorrasAGHollandSDGertzBJPharmacokinetics of alendronateClin Pharmacokinet199936531532810384857
   PubMed Web of Science ®Google Scholar
• PeterCPHandtLKSmithSMEsophageal irritation due to alendronate sodium tablets: possible mechanismsDig Dis Sci1998439199820029753265
   PubMed Web of Science ®Google Scholar
• BoneHGAdamiSRizzoliRWeekly administration of alendronate: rationale and plan for clinical assessmentClin Ther2000221152810688387
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging200012111210746426
   PubMedGoogle Scholar
• RizzoliRGreenspanSLBoneG3rdAlendronate Once-Weekly Study GroupTwo-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisJ Bone Miner Res200217111988199612412806
   PubMed Web of Science ®Google Scholar
• UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab200523538238816133688
   PubMed Web of Science ®Google Scholar
• LuckeyMKaganRGreenspanSOnce-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosisMenopause200411440541515243278
   PubMed Web of Science ®Google Scholar
• ReidDMHoskingDKendlerDA comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-InternationalInt J Clin Pract200862457558418324951
   PubMed Web of Science ®Google Scholar
• ChesnutIII CHSkagAChristiansenCOral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• DelmasPDReckerRRChesnutCHIIIDaily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE studyOsteoporos Int2004151079279815071723
   PubMed Web of Science ®Google Scholar
• ReckerRRGallagherRMacCosbePEEffect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc200580785686116007889
   PubMed Web of Science ®Google Scholar
• CramerJAAmonkarMMHebbornAAltmanRCompliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin20052191453146016197664
   PubMed Web of Science ®Google Scholar
• CramerJASilvermanSPersistence with bisphosphonate treatment for osteoporosis: finding the root of the problemAm J Med20061194 Suppl 1S12S1716563936
   PubMed Web of Science ®Google Scholar
• BriesacherBAAndradeSEHarroldLRFouayziHYoodRAAdoption of once-monthly oral bisphosphonates and the impact on adherenceAm J Med2010123327528020193837
   PubMed Web of Science ®Google Scholar
• ReddyGTKumarTMVeenaFormulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in PeriodontitisDrug Deliv200512421722216044536
   PubMed Web of Science ®Google Scholar
• SharmaAPradeepARClinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trialJ Periodontol2012831111821542734
   PubMed Web of Science ®Google Scholar
• ShirakiMNakamuraTFukunagaMSoneTUsamiAInoueTA multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis – monthly (four weeks) intravenous versus once weekly oral administrationsCurr Med Res Opin20122881357136722769235
   PubMed Web of Science ®Google Scholar
• ImaiKManagement of osteoporosis: assessment of fracture risk and therapeutic effects on osteoporosisPenaARPerezVOOsteoporosis: Risk Factors, Symptoms and ManagementNew YorkNova Science20126791
   Google Scholar